Australian Institute of Health Innovation, Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, NSW, Australia
Australian Institute of Health Innovation, Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, NSW, Australia.
BMJ Health Care Inform. 2021 Apr;28(1). doi: 10.1136/bmjhci-2020-100301.
To examine how and to what extent medical devices using machine learning (ML) support clinician decision making.
We searched for medical devices that were (1) approved by the US Food and Drug Administration (FDA) up till February 2020; (2) intended for use by clinicians; (3) in clinical tasks or decisions and (4) used ML. Descriptive information about the clinical task, device task, device input and output, and ML method were extracted. The stage of human information processing automated by ML-based devices and level of autonomy were assessed.
Of 137 candidates, 59 FDA approvals for 49 unique devices were included. Most approvals (n=51) were since 2018. Devices commonly assisted with diagnostic (n=35) and triage (n=10) tasks. Twenty-three devices were assistive, providing decision support but left clinicians to make important decisions including diagnosis. Twelve automated the provision of information (autonomous information), such as quantification of heart ejection fraction, while 14 automatically provided task decisions like triaging the reading of scans according to suspected findings of stroke (autonomous decisions). Stages of human information processing most automated by devices were information analysis, (n=14) providing information as an input into clinician decision making, and decision selection (n=29), where devices provide a decision.
Leveraging the benefits of ML algorithms to support clinicians while mitigating risks, requires a solid relationship between clinician and ML-based devices. Such relationships must be carefully designed, considering how algorithms are embedded in devices, the tasks supported, information provided and clinicians' interactions with them.
探讨使用机器学习 (ML) 的医疗器械如何以及在何种程度上支持临床医生做出决策。
我们搜索了截至 2020 年 2 月获得美国食品和药物管理局 (FDA) 批准的医疗器械,这些医疗器械(1)已获得 FDA 批准;(2)供临床医生使用;(3)用于临床任务或决策;(4)使用 ML。提取了有关临床任务、设备任务、设备输入和输出以及 ML 方法的描述性信息。评估了基于 ML 的设备自动化的人类信息处理阶段和自主程度。
在 137 个候选者中,有 59 个 FDA 批准了 49 个独特的设备。大多数批准(n=51)是在 2018 年之后。设备常用于辅助诊断(n=35)和分诊(n=10)任务。23 个设备具有辅助功能,提供决策支持,但让临床医生做出重要决策,包括诊断。12 个设备自动提供信息(自主信息),例如量化心脏射血分数,而 14 个设备自动提供任务决策,例如根据疑似中风发现对扫描进行分诊(自主决策)。设备自动化程度最高的人类信息处理阶段是信息分析(n=14),即将信息作为输入提供给临床医生决策,以及决策选择(n=29),设备提供决策。
在减轻风险的同时利用 ML 算法的优势来支持临床医生,需要临床医生和基于 ML 的设备之间建立牢固的关系。这些关系必须精心设计,考虑算法如何嵌入设备、支持的任务、提供的信息以及临床医生与它们的交互方式。